Primary Care Perspectives on Alzheimer’s Disease: Adaptive Strategies to Improve Cognitive Assessment, Promote Earlier Diagnosis, and Optimize Care

• Review the etiology, epidemiology, and multifaceted pathophysiology of Alzheimer’s disease (AD), highlighting pathologic processes that may manifest years before symptom onset.
• Discuss the paramount importance of symptom recognition and routine screening protocols to identify mild cognitive impairment (MCI) and promote early AD diagnosis.
• Evaluate currently-available cognitive assessment tools, with an emphasis on those best suited for the primary care setting, and summarize expert consensus AD diagnostic criteria across the disease continuum.
• Examine how biomarker-driven disease characterization, including blood-based metrics, supports timely and accurate AD diagnosis and treatment initiation.
• Use real-world cases from the primary care perspective to design evidence-supported and patient-centric diagnostic plans that incorporate shared decision making and multidisciplinary and interprofessional referrals.

Supported through an independent educational grant from Genentech.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planner:
Mark J. Huffmyer, PharmD, BCGP, BCACP–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty:
Alireza Atri, MD, PhD–disclosures to come.

Peer Reviewer:
Information to come.

CEC Staff/Planners:
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.